IGF-II-Conjugated Nanocarrier for Brain-Targeted Delivery of p11 Gene for Depression
- 121 Downloads
Gene therapy involving p11 cDNA has been thought to be a futuristic approach for the effective management of depression as the existing treatment regimen presents many issues regarding late onset of action, patient withdrawal and their side effects. For the effective transfection of p11 gene intracellularly, two cationic lipids based on phospholipid DOPE conjugated to basic amino acids histidine and arginine were synthesised, used for liposome formulation and evaluated for their ability as gene delivery vectors. They were further converted using IGF-II mAb into immunoliposomes for CNS targeting and mAb conjugation to liposomes were characterised by SDS-PAGE. They were further analysed by in vitro characterisation studies that include erythrocyte aggregation study, electrolyte-induced study, heparin compatibility study and serum stability studies. SHSY5Y cells were used for conducting cytotoxicity of synthesised lipids and live imaging of cell uptake for 25 min. Finally, the brain distribution studies and western blot were carried out in animals to evaluate them for their BBB permeation ability and effects on p11 protein which is believed to be a culprit. These formulated liposomes from synthesised lipids offer a promising approach for the treatment of depression.
KEY WORDSgene therapy depression CNS targeting liposomes p11 gene
The authors would like to thank the Department of Chemistry and Biochemistry, The Maharaja Sayajirao University of Baroda, Vadodara, for the help in carrying out lipid synthesis and plasmid isolation respectively.
Compliance with Ethical Standards
The protocol for the study was duly approved by Institutional Animal Ethics Committee, Faculty of Pharmacy, The M. S. University of Baroda, Vadodara, vide protocol approval no: MSU/IAEC/2016-17/1631.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 6.Fitzsimmons R. Novel polymer and lipid-based nanocarriers for gene delivery. 2011.Google Scholar
- 9.Vhora I, Lalani R, Bhatt P, Patil S, Patel H, Patel V, et al. Colloidally stable small unilamellar stearyl amine lipoplexes for effective BMP-9 gene delivery to stem cells for osteogenic differentiation. AAPS PharmSciTech. 2018. https://doi.org/10.1208/s12249-018-1161-6.
- 13.Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: enhanced loading efficiency and its pharmacokinetic evaluation. Int J Pharm. 2018;536(1):95–107. https://doi.org/10.1016/j.ijpharm.2017.11.048.CrossRefPubMedGoogle Scholar
- 15.Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved <em>in vitro</em> efficacy on ovarian cancer cells. Cancer Res. 2016;76(14 Supplement):2065. https://doi.org/10.1158/1538-7445.am2016-2065.CrossRefGoogle Scholar
- 18.Sölch S. Effects of the GTPase Rab31 on breast cancer cell proliferation, adhesion, and expression of other tumor-associated genes. Munich: Technische Universität München; 2014.Google Scholar
- 19.Sasse J, Gallagher SR. Staining proteins in gels. Curr Protoc Mol Biol. 2009;10:6. 1–6. 27.Google Scholar
- 34.Tandel H, Bhatt P, Jain K, Shahiwala A, Misra A. In-vitro and in-vivo tools in emerging drug delivery scenario: challenges and updates. In: Misra ASA, editor. In-vitro and in-vivo tools in drug delivery research for optimum clinical outcomes. Boca Raton: CRC Press; 2018.Google Scholar